Posts Tagged ‘jones-newswires’
-
Thursday, May 27th, 2010 at 02:48 | Comments Off
London Calling: Pfizer’s Mackay to Head R&D at AstraZenecaCategories: Wall Street Journal
Pfizer exec Martin Mackay is decamping for cross-Atlantic rival AstraZeneca, where he’ll be president of R&D, a new position, Dow Jones Newswires reports.
Mackay held the same title at Pfizer from 2007 to 2009, but in the wake of the company’s Wyeth acquisition, he split the top job …
View original post here: London Calling: Pfizer’s Mackay to Head R&D at AstraZeneca
-
Wednesday, May 12th, 2010 at 03:47 | Comments Off
Boston Scientific to News Media: No Annual Meeting for You!Categories: Wall Street Journal -
Thursday, April 22nd, 2010 at 02:17 | Comments Off
Health-Care Overhaul and Pharma Outlook: A ScorecardCategories: Wall Street Journal
Abbott is the latest drug maker to reduce its outlook because of health-care overhaul elements such as immediate increases in Medicaid discounts. Here’s the Dow Jones Newswires story.
As earnings season continues, we’ll track what pharma companies are saying about the near-term impact of legislation on its sales and earnings. Yesterday Johnson & Johnson predicted the industry as a whole would lose about $4 billion in 2010 sales and $11 billion in 2011 sales due to the new law.
Here’s what we ..read more
-
Wednesday, April 21st, 2010 at 23:50 | Comments Off
Study: ‘Brain Games’ Won’t Make You SmarterCategories: Wall Street Journal
It turns out those computer games that are supposed to increase cognitive skills through short-term memory, problem-solving, and visual-spatial skills exercises actually do something: They improve users’ prowess in short-term memory, problem-solving and visual-spatial skills exercises.
They do not, however, improve “mental fitness” beyond boosting performance on the tests used in the program, the WSJ reports. A study published in Nature took 11,430 healthy participants and randomly assigned them to one of three regimens: online games aimed at increasing general cognitive ..read more
-
Thursday, April 8th, 2010 at 02:57 | Comments Off
FDA Issues Warning Letters Over Tysabri, ‘Lipodissolve’ InjectionsCategories: Wall Street Journal
The FDA today disclosed several warning letters it had sent to drug makers and weight-loss spas for “false” and-or “misleading” claims for their products. Here’s a rundown:
Biogen Idec was cited for a promotional Webcast involving the multiple sclerosis drug Tysabri because it minimized the risk of a serious brain infection, the FDA said. The letter also cited the company for failing to submit the Webcast for FDA review 30 days in advance. Tysabri is sold jointly by Biogen and ..read more -
Wednesday, March 31st, 2010 at 03:07 | Comments Off
FDA Roundup: Menthol Cigarettes, CT Scans, No Go on Jet-Lag DrugCategories: Wall Street Journal
A few items of interest involving the FDA:
Congress last year added the tobacco industry to the FDA’s regulatory mix and today a panel of health experts making up the agency’s new Tobacco Products Scientific Advisory Committee is kicking off a two-day meeting. First on the agenda: how menthol flavoring in cigarettes affects smokers’ habits.
Small wonder that menthol is getting early attention, says the New York Times, which notes menthol butts account for almost a third of the $70 billion U.S. ..read more
-
Thursday, March 25th, 2010 at 02:58 | Comments Off
Genzyme Faces FDA Enforcement Moves Over Production ProblemsCategories: Wall Street Journal
Fallout from Genzyme’s production problems at its Allston, Mass., plant continue to bedevil the company, which announced it faces a slew of enforcements actions by the FDA.
The details of the regulatory actions are yet to come. But Genzyme said it was told by the FDA that the moves probably will include a consent decree under which a third-party watchdog would monitor the plant’s operations “for an extended period” and decide if it’s living up to FDA rules. “Genzyme also would ..read more
-
Thursday, March 25th, 2010 at 01:45 | Comments Off
Nursing Homes Chafe Under Drug-Prescribing RulesCategories: Wall Street Journal, aging
Agents of the Drug Enforcement Administration have been pushing harder to investigate cases of nursing-home staff giving powerful medications to patients without a doctor’s prescription. But if that sounds all well and good, some say it’s just the nub of a more-complicated situation.
Trade groups for nursing homes and hospice-care facilities say “patients have been left to ‘languish in pain’ while nursing homes and pharmacies try to find ways to comply with DEA regulations requiring physicians, in most cases, to write ..read more
-
Saturday, March 20th, 2010 at 09:15 | Comments Off
Why Doing Someting About ‘Pay for Delay’ Will Have to WaitCategories: Wall Street Journal
Amid all the ink going to what the proposed health-care overhaul would do, we wanted to note an easy-to-overlook provision that it won’t do: eliminate many so-called pay-for-delay deals.
Those are the oft-criticized pacts under which branded drug makers give something to generic makers stall cheaper copycat versions coming on the market. The deals, which usually involve settlements of patent disputes between the generic and branded drug makers, result in consumers paying the higher branded prices until the generic counterparts arrive.
President ..read more
-
Friday, March 19th, 2010 at 00:29 | Comments Off
Teva Outwrestles Pfizer to Land Generics Maker RatiopharmCategories: Wall Street Journal
The world’s biggest generic drug maker is getting bigger with the announcement this morning that Israel’s Teva Pharmaceutical had won the bidding against Pfizer for Germany’s Ratiopharm Group. The pricetag: $4.97 billlion.
A bidding contest had been dragging on for months for Ratiopharm, the world’s sixth largest generics maker. The deal is the biggest takeover in the generic drugs market since Teva bought U.S.-based Barr Pharmaceuticals for $7.46 billion in 2008.
Others interested in the company included another generic maker, Actavis Group ..read more

